广东汉族人纤溶酶原激活剂抑制物-1基因4G/5G多态性与2型糖尿病肾病的相关性

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (08): 904-907.

广东汉族人纤溶酶原激活剂抑制物-1基因4G/5G多态性与2型糖尿病肾病的相关性

刘仕群¹, 薛耀明¹, 杨光彩², 何飞英¹, 赵小山³

1. 第一军医大学南方医院内分泌科, 广东, 广州, 510515;
2. 第一军医大学生物化学与分子生物学教研室, 广东, 广州, 510515;
3. 第一军医大学南方医院中医科, 广东, 广州, 510515

出版日期:2004-08-20 发布日期:2004-08-20
基金资助:
收稿日期:2004-2-1。
基金项目:广东省重点攻关项目
作者简介:刘仕群(1964-),主治医师,讲师

Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province

LIU Shi-qun¹, XUE Yao-ming¹, YANG Guang-cai², HE Fei-ying¹, ZHAO Xiao-shan³

1. 第一军医大学南方医院内分泌科, 广东, 广州, 510515;
2. 第一军医大学生物化学与分子生物学教研室, 广东, 广州, 510515;
3. 第一军医大学南方医院中医科, 广东, 广州, 510515

Online:2004-08-20 Published:2004-08-20

摘要/Abstract

摘要： 目的探讨纤溶酶原激活剂抑制物-1(PAI-1)基因4G/5G多态性与广东汉族人2型糖尿病肾病(DN)发病的关系。方法采用聚合酶链反应-限制性片段长度多态性分析,对147例病史7年以上的2型糖尿病患者[其中DN患者77例,糖尿病非肾病(DNN)患者70例]和26名健康人进行了PAI-1基因4G/5G多态性分析。结果 DNN组PAI-1基因的4G/4G基因型、基因频率显著高于DN组(χ²=13.008,P<0.01);与5G/5G基因型相比,DNN组PAI-1基因4G/4G型对DN组的比数比为1.447,95%的可信区间0.533~3.934(P<0.05),差异有显著性。而DN与DNN组PAI-1基因4G等位基因频率无显著差异(χ²=1.22,P>0.05);结论 PAI-1基因4G/4G基因型与广东汉族人2型DN的发病有关联,4G/4G基因型广东汉族2型糖尿病人易发生DN。

Abstract: Objective To understand the association between plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G polymorphism and type 2 diabetic nephropathy (DN) in Chinese Han patients in Guangdong Province. Methods PAI-1 gene 4G/5G polymorphism was analyzed in 26 normal individuals, 77 patients with type 2 diabetic nephropathy and 70 type 2 diabetic patients without nephropathy (DNN) by polymerase chain reaction-restriction fragment length polymorphism. Results The 4G/4G genotype frequencies of PAI-1 gene were higher in DN than in DNN patients (0.390 vs 0.171, χ²=13.008, P<0.01), with the odds ratio (OR) of 1.447 (95% confidence interval: 0.533-3.934, P<0.05) in comparison with 5G/5G genotypes between the 2 patient groups. The 4G allele frequencies of PAI-1 gene were similar in DN and DNN groups (0.57 vs 0.51,χ²=1.22, P>0.05). Conclusion The PAI-1 4G/4G genotype is associated with increased risk for type 2 DN the Chinese Han population in Guangdong Province, and type 2 diabetic patients with 4G/4G PAI-1 genotype are more likely to develop DN than those with 5G/5G PAI-1 genotype.

中图分类号:

R692.39

刘仕群¹, 薛耀明¹, 杨光彩², 何飞英¹, 赵小山³. 广东汉族人纤溶酶原激活剂抑制物-1基因4G/5G多态性与2型糖尿病肾病的相关性[J]. 南方医科大学学报, 2004, 24(08): 904-907.

LIU Shi-qun¹, XUE Yao-ming¹, YANG Guang-cai², HE Fei-ying¹, ZHAO Xiao-shan³. Relationship between plasminogen activator inhibitor-1 gene 4G/5G polymorphism and type 2 diabetic nephropathy in Chinese Han patients in Guangdong Province[J]. Journal of Southern Medical University, 2004, 24(08): 904-907.

参考文献

[1] Gunter W, Fuad NZ. Molecular mechanisms of diabetic renal hypertrophy[J]. Kidney Iht, 1999, 56: 393-405.
[2] Wong TY, Poon P, Szeto CC, et al. Association ofplasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients[J]. Kidney Iht, 2000, 57: 632-8.
[3] 管立学,季祥武,王敬先,等.纤溶酶原激活剂抑制物-1基因启动子因-6754G/5G多态性与中国人冠心病的关联研究[J].中华医学遗传学杂志,2002,19:393-6.Guan LX, Ji XW, Wang JX, et al. Association ofplasminogen activator inhibitor-1 gene 4G/5G polymorphism and coronary heart disease in Chinese patients[J]. Chin J Med Genet, 2002, 19: 393-6.
[4] Baricos WH, Cortez SL, El-dahr SS, et al. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2cascade[J]. Kidney Int, 1995, 47: 1039-47.
[5] Anglfs CE, Rondeau E, Delarue F, et al. Identification and cellular localization of plasminogen activator of the human glomeruli[J].Thromb Haemost, 1985, 54: 688-92.
[6] Dawson S, Hamsten A, Wiman B, et al: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasminogen activator inhibitor- 1 activity[J]. Artefioscler Thromb, 1991, 11: 183-90.
[7] Raptis AE. Viberti G. Pathogenesis of diabetic nephropathy[J]. Exp Clin Endocrinol Diabetes, 2001, 109(Suppl 2): S424-37.
[8] Margalion M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G is associated with a family history of coronary artery disease[J]. Arterioscler Thromb Vasc Biol, 1998, 18: 152-6.
[9] Mikkelsson J, Perola M, Wartiovaarau U, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis,and myocardial infarction in middle-aged Finnish men who died suddenly[J]. Thrpmb Haemost, 2000, 84: 78-82.
[10] Menges T, Hermans PW, Little SG, et al. Plasminogen-activatorinhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients[J]. Lancet, 2001, 357: 1096-7.